[go: up one dir, main page]

CU20120158A7 - POLIPÉPTIDOS DERIVADOS DEL TGFß - Google Patents

POLIPÉPTIDOS DERIVADOS DEL TGFß

Info

Publication number
CU20120158A7
CU20120158A7 CUP2012000158A CU20120158A CU20120158A7 CU 20120158 A7 CU20120158 A7 CU 20120158A7 CU P2012000158 A CUP2012000158 A CU P2012000158A CU 20120158 A CU20120158 A CU 20120158A CU 20120158 A7 CU20120158 A7 CU 20120158A7
Authority
CU
Cuba
Prior art keywords
polypeptides
tgfβ
alk5
pharmaceutical compositions
fusion proteins
Prior art date
Application number
CUP2012000158A
Other languages
English (en)
Other versions
CU24181B1 (es
Inventor
Osorio Ángel De Jesús Corria
Monzón Kalet León
Portilla Tania Carmenate
Meriño Amaury Pupo
Rodríguez Saumel Pérez
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120158(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CU20120158A priority Critical patent/CU24181B1/es
Priority to JP2015540045A priority patent/JP6298823B2/ja
Priority to ES13805228T priority patent/ES2857176T3/es
Priority to MX2015005875A priority patent/MX366060B/es
Priority to CN201380058181.7A priority patent/CN104902916B/zh
Priority to KR1020157011131A priority patent/KR102093494B1/ko
Priority to EP13805228.7A priority patent/EP2918284B1/en
Priority to US14/440,627 priority patent/US9701730B2/en
Priority to SG11201502980VA priority patent/SG11201502980VA/en
Priority to BR112015010145-3A priority patent/BR112015010145B1/pt
Priority to HK16101766.2A priority patent/HK1213781B/xx
Priority to MYPI2015701369A priority patent/MY173078A/en
Priority to AU2013344022A priority patent/AU2013344022B2/en
Priority to NZ707850A priority patent/NZ707850A/en
Priority to PCT/CU2013/000007 priority patent/WO2014071894A1/es
Priority to EA201590914A priority patent/EA031990B1/ru
Priority to PE2015000549A priority patent/PE20150890A1/es
Priority to UAA201505566A priority patent/UA115678C2/uk
Priority to CA2887455A priority patent/CA2887455C/en
Priority to JOP/2013/0317A priority patent/JO3502B1/ar
Priority to TW102140494A priority patent/TWI615404B/zh
Priority to ARP130104078A priority patent/AR093391A1/es
Publication of CU20120158A7 publication Critical patent/CU20120158A7/es
Priority to TNP2015000129A priority patent/TN2015000129A1/fr
Priority to PH12015500807A priority patent/PH12015500807A1/en
Priority to CO15095702A priority patent/CO7400865A2/es
Priority to IL238621A priority patent/IL238621B/en
Priority to CL2015001252A priority patent/CL2015001252A1/es
Priority to ZA2015/04462A priority patent/ZA201504462B/en
Publication of CU24181B1 publication Critical patent/CU24181B1/es
Priority to JP2018031896A priority patent/JP6608473B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con las ramas de la Biotecnología y particularmente con polipéptidos mutados de la molécula TGFß cuya secuencia primaria tiene una alta homología con la secuencia del TGFß humano. Estas muteínas pierden la capacidad de interacción con ALK5 pero conservan la interacción con el resto de los receptores que forman parte del complejo receptor (TßEII y TßRII). Tienen la propiedad de antagonizar la señalización de todas las variantes naturales de los ligandos TGFß, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador. La presente invención se relaciona con composiciones farmacéuticas que comprenden como principio activo los polipétidos o proteínas de fusión divulgados y con el uso terapéutico de los polipéptidos, proteínas de fusión y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como el cáncer, enfermedades que cursan con fibrosis y en enfermedades infecciosas crónicas.
CU20120158A 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß CU24181B1 (es)

Priority Applications (29)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PE2015000549A PE20150890A1 (es) 2012-11-09 2013-10-30 POLIPEPTIDOS DERIVADOS DEL TGFß Y SUS USOS
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS
EA201590914A EA031990B1 (ru) 2012-11-09 2013-10-30 МУТАНТНЫЕ ПОЛИПЕПТИДЫ TGFβ И ИХ ПРИМЕНЕНИЕ
MX2015005875A MX366060B (es) 2012-11-09 2013-10-30 Polipéptidos derivados de tgfbeta y sus usos.
CN201380058181.7A CN104902916B (zh) 2012-11-09 2013-10-30 衍生自TGFβ的多肽及其用途
KR1020157011131A KR102093494B1 (ko) 2012-11-09 2013-10-30 TGFβ-유래 폴리펩티드 및 이들의 용도
EP13805228.7A EP2918284B1 (en) 2012-11-09 2013-10-30 Polypeptides derived from tgf and uses thereof
US14/440,627 US9701730B2 (en) 2012-11-09 2013-10-30 TGFβ-derived polypeptides and uses thereof
SG11201502980VA SG11201502980VA (en) 2012-11-09 2013-10-30 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
BR112015010145-3A BR112015010145B1 (pt) 2012-11-09 2013-10-30 Polipeptídeo, e, composição farmacêutica para o tratamento de câncer
HK16101766.2A HK1213781B (en) 2012-11-09 2013-10-30 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
MYPI2015701369A MY173078A (en) 2012-11-09 2013-10-30 Tgf?-derived polypeptides and uses thereof
AU2013344022A AU2013344022B2 (en) 2012-11-09 2013-10-30 Polypeptides derived from TGFBETA and uses thereof
NZ707850A NZ707850A (en) 2012-11-09 2013-10-30 Polypeptides derived from tgfβ and uses thereof
JP2015540045A JP6298823B2 (ja) 2012-11-09 2013-10-30 ＴＧＦβに由来するポリペプチド及びその使用
UAA201505566A UA115678C2 (uk) 2012-11-09 2013-10-30 МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ
CA2887455A CA2887455C (en) 2012-11-09 2013-10-30 Polypeptides derived from tgf.beta. and uses thereof
ES13805228T ES2857176T3 (es) 2012-11-09 2013-10-30 Polipéptidos derivados de TGF y usos de los mismos
JOP/2013/0317A JO3502B1 (ar) 2012-11-09 2013-11-03 البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها
TW102140494A TWI615404B (zh) 2012-11-09 2013-11-07 轉變生長因子β（ＴＧＦβ）衍生之多肽類及彼等之用途
ARP130104078A AR093391A1 (es) 2012-11-09 2013-11-07 POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS
TNP2015000129A TN2015000129A1 (en) 2012-11-09 2015-04-03 POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
PH12015500807A PH12015500807A1 (en) 2012-11-09 2015-04-13 Tgf�-derived polypeptides and uses thereof
CO15095702A CO7400865A2 (es) 2012-11-09 2015-04-28 Polipeptidos derivados del tgfbeta y sus usos
IL238621A IL238621B (en) 2012-11-09 2015-05-04 Polypeptides derived from tgfß– and their uses
CL2015001252A CL2015001252A1 (es) 2012-11-09 2015-05-08 Polipéptido que antagoniza la actividad de los ligando tgf beta naturales mediada por el receptor alk5; composición farmacéutica que lo comprende; y sus usos.
ZA2015/04462A ZA201504462B (en) 2012-11-09 2015-06-08 TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
JP2018031896A JP6608473B2 (ja) 2012-11-09 2018-02-26 ＴＧＦβに由来するポリペプチド及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Publications (2)

Publication Number Publication Date
CU20120158A7 true CU20120158A7 (es) 2014-06-27
CU24181B1 CU24181B1 (es) 2016-04-25

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Country Status (27)

Country Link
US (1) US9701730B2 (es)
EP (1) EP2918284B1 (es)
JP (2) JP6298823B2 (es)
KR (1) KR102093494B1 (es)
CN (1) CN104902916B (es)
AR (1) AR093391A1 (es)
AU (1) AU2013344022B2 (es)
BR (1) BR112015010145B1 (es)
CA (1) CA2887455C (es)
CL (1) CL2015001252A1 (es)
CO (1) CO7400865A2 (es)
CU (1) CU24181B1 (es)
EA (1) EA031990B1 (es)
ES (1) ES2857176T3 (es)
IL (1) IL238621B (es)
JO (1) JO3502B1 (es)
MX (1) MX366060B (es)
MY (1) MY173078A (es)
NZ (1) NZ707850A (es)
PE (1) PE20150890A1 (es)
PH (1) PH12015500807A1 (es)
SG (1) SG11201502980VA (es)
TN (1) TN2015000129A1 (es)
TW (1) TWI615404B (es)
UA (1) UA115678C2 (es)
WO (1) WO2014071894A1 (es)
ZA (1) ZA201504462B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541409B1 (en) * 2016-11-18 2025-01-22 University of Pittsburgh- Of the Commonwealth System of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna
CN119285746B (zh) * 2024-10-24 2026-01-30 湖南中晟全肽生物科技股份有限公司 作为TGF-β受体激动剂肽的化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065948A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US7470769B2 (en) * 2004-06-30 2008-12-30 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
WO2006076041A2 (en) * 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂

Also Published As

Publication number Publication date
KR102093494B1 (ko) 2020-03-26
WO2014071894A1 (es) 2014-05-15
CN104902916B (zh) 2018-04-13
US9701730B2 (en) 2017-07-11
IL238621A0 (en) 2015-06-30
PE20150890A1 (es) 2015-06-10
JP6298823B2 (ja) 2018-03-20
AU2013344022A1 (en) 2015-05-28
NZ707850A (en) 2019-08-30
EP2918284B1 (en) 2021-02-17
PH12015500807A1 (en) 2015-06-08
MX366060B (es) 2019-06-26
EA201590914A1 (ru) 2015-09-30
ES2857176T3 (es) 2021-09-28
AR093391A1 (es) 2015-06-03
BR112015010145A2 (es) 2017-08-22
UA115678C2 (uk) 2017-12-11
US20150284441A1 (en) 2015-10-08
KR20150083848A (ko) 2015-07-20
CN104902916A (zh) 2015-09-09
HK1213781A1 (zh) 2016-07-15
JP2015535000A (ja) 2015-12-07
TW201431875A (zh) 2014-08-16
JP6608473B2 (ja) 2019-11-20
TWI615404B (zh) 2018-02-21
SG11201502980VA (en) 2015-06-29
BR112015010145B1 (pt) 2022-06-07
CA2887455C (en) 2022-05-17
CL2015001252A1 (es) 2015-07-17
CA2887455A1 (en) 2014-05-15
EA031990B1 (ru) 2019-03-29
IL238621B (en) 2019-12-31
AU2013344022B2 (en) 2016-12-15
MX2015005875A (es) 2015-09-10
CO7400865A2 (es) 2015-09-30
EP2918284A1 (en) 2015-09-16
TN2015000129A1 (en) 2016-10-03
ZA201504462B (en) 2018-11-28
JP2018111703A (ja) 2018-07-19
MY173078A (en) 2019-12-25
JO3502B1 (ar) 2020-07-05
CU24181B1 (es) 2016-04-25

Similar Documents

Publication Publication Date Title
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
MX2016009809A (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
MX2019006733A (es) Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX387450B (es) Regimenes de dosificacion para compuestos de la clase de las equinocandinas.
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
CU23923B1 (es) Polipéptidos derivados de la il-2 con actividad agonista
EA202090699A2 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
MX2019005269A (es) Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.
EP2889308A4 (en) CONEPOXIN PEPTIDE OF THE ALPHA O-SUPERFAMILY, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
AR095527A1 (es) Formulaciones de polipéptido fc-factor ix
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.

Legal Events

Date Code Title Description
FG Grant of patent